In the last #KidneyKompass @brendonneuen.bsky.social chats with Sophia Zoungas podcasts.apple.com/ca/podcast/k... on the SURPASS data G-force FTW @christosargyrop.bsky.social @rnflex.bsky.social Hey @brianrifkin.bsky.social if sema is captopril what would you call dulaglutide? 😏

New Global Burden of Disease report on CKD. Up to 9th leading cause of mortality in adults 😢 #kidneyweek www.thelancet.com/action/showP...

Loved watching @kidneyrebel.bsky.social grand rounds at @nu-nephrology.bsky.social!! Thank you for the PKD mega blocks shout out #nephjc (1), happy to be at the right overlap in my Venn diagram (2), and trying to build toward a medical specialty in a hill (3) www.youtube.com/watch?v=RlTC...

Huge congratulations Mike and Lonnie.

IMJ June 2025 #OpenAccess Editor's choice (original article): Smoking and kidney transplantation wait listing bit.ly/4kFslsJ @theracp.bsky.social @sunilbadve.bsky.social

IMJ June 2025 #FreeAccess Editorial: Smokers and kidney transplantation assessment: a question of risk or equity? bit.ly/3FUCH8Q @theracp.bsky.social @sunilbadve.bsky.social

It's been a long journey but today we can share the methods and rationale for the #ACHIEVEtrial (Spiro vs placebo for patients with kidney failure receiving maintenance dialysis) and tomorrow we share the results at #era25 journals.sagepub.com/doi/10.1177/...

Save the date for Kidney Supportive Care Masterclass 2025 and Serious Illness Conversations Workshop. Open to nephrologists, nephrology trainees and nurse practitioners. Separate registrations for the Masterclass (forms.office.com/r/L90B6DrscS) and the Workshop (email in the image).

This one is a no-brainer Become an FASN @asnkidney.bsky.social My pitch at the last #KidneyWk youtu.be/9uzq2KIjuNk?... #NephSky (h/t @sunilbadve.bsky.social )

📢 New Systematic Review & Meta-Analysis in @kireports.bsky.social 📢 We evaluated the effects of iron therapy on clinical outcomes in chronic kidney disease (CKD), analyzing 45 randomized trials. A summary of our findings: 🧵 www.kireports.org/article/S246...

The UKKA AKI report is out, h/t @beckybonfield.bsky.social @ukkidney.org www.ukkidney.org/sites/defaul... (PDF) Incl. - Don’t call RAASi nephrotoxic - Don’t delay contrast imaging - Sick day rules are mostly 🐴 💩

In people with T2D, effects of GLP1-RA on CV, kidney & mortality outcomes are consistent irrespective of SGLT2i Our meta-analysis of the 3 GLP1RA diabetes clinical outcome trials with the largest prevalent use of SGLT2i in @ahajournals.bsky.social Circulation www.ahajournals.org/doi/10.1161/...

Clear ⏬ with GLP-1RA by ~15% for all clinical outcomes including: Kidney failure ✅ Major CV events ✅ Heart failure ✅ CV death ✅ All-cause death ✅ Updated systematic review/meta-analysis of 11 trials ~85,000 participants, with & without diabetes Now in Lancet D&E: www.thelancet.com/journals/lan...

Sharing the free access link here (for 50 days only) authors.elsevier.com/a/1k9u77tNuc...

Wishing the Elsevier editors who desk-accepted this all the best for their next career moves. doi.org/10.1016/j.ij...

Good morning! Nov 15 AM update: The 3rd Nephrology pack is well known its way: go.bsky.app/2yLiYN4 Second pack go.bsky.app/N27Kzri First pack: go.bsky.app/H4td28C Hypertension Nerds go.bsky.app/KBLojr Kidney/HT Journals go.bsky.app/2BG7wKr Please reply or DM me to be added!